je.st
news
Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer ...
2015-12-09 01:44:52| Biotech - Topix.net
Oncothyreon Inc. , a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the lives and outcomes of patients with cancer, today announced updated data from the company's ongoing trials of ONT-380, an orally active, reversible and selective small-molecule HER2 inhibitor being developed for the treatment of HER2-positive metastatic breast cancer. The data will be the subject of two presentations at the San Antonio Breast Cancer Symposium being held December 8-12, 2015 in San Antonio, TX.
Tags: data
cancer
breast
announces
Category:Biotechnology and Pharmaceuticals